MO
PFE icon

McMillan Office’s Pfizer PFE Stock Holding History

McMillan Office’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.32M Sell
345,681
-4,912
-1% -$128K 0.96% 22
2026
Q1 		$9.84M Sell
350,593
-13,034
-4% -$347K 1.26% 18
2025
Q4 		$9.05M Buy
+363,627
New +$9.17M 1.09% 19

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

McMillan Office's PFE Position: Q2 2026 in Review

McMillan Office reduced its Pfizer (PFE) stake by 1.4% in Q2 2026, selling an estimated $128K and leaving 345,681 shares worth $8.32M. The position accounts for 0.96% of the portfolio, ranked #22.

McMillan Office first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.84M in Q1 2026. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • McMillan Office held 345,681 shares of Pfizer worth $8.32M as of Q2 2026.
  • McMillan Office sold 4,912 Pfizer shares in Q2 2026, an estimated $128K.
  • Pfizer made up 0.96% of McMillan Office's portfolio in Q2 2026, its #22 holding.
  • McMillan Office first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
  • McMillan Office's Pfizer position peaked at $9.84M in Q1 2026.
  • 2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.